Detail akcie Anika Therapeut online

Business Summary: Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Anika Therapeutics Inc revenues increased 14% to $62.2M. Net loss before extraordinary items decreased 80% to $1.7M. Revenues reflect OEM Channel segment increase of 14% to $35.7M, Commercial Channel segment increase of 14% to $26.5M, United States segment increase of 12% to $38.3M, Europe segment increase of 28% to $13.5M. Lower net loss reflects Selling.